• Exploration of Targeted Anti-tumor Therapy

    eISSN: 2692-3114
    EiC: Nicola Normanno, MD
    Frequency: Bimonthly
    APC: No Article Processing Charge
    Publishing Model: Open Access
    Peer Review Model: Single Blind
    Indexing & Archiving: PubMed/PMC, Scopus (Newly Accepted), DOAJ, CAS, etc.
    Follow the journal:
    Follow the journal:
    Articles
    Open Access
    Original Article
    N6-methyladenosine-related microRNAs risk model trumps the isocitrate dehydrogenase mutation status as a predictive biomarker for the prognosis and immunotherapy in lower grade gliomas
    Aim: Lower grade gliomas [LGGs; World Health Organization (WHO) grades 2 and 3], owing to the heterogeneity of their clinical behavior, present a therapeutic challenge to  [...] Read more.
    Feng Yuan ... Chiyuan Ma
    Published: September 30, 2022 Explor Target Antitumor Ther. 2022;3:553–569
    DOI: https://doi.org/10.37349/etat.2022.00100
    This article belongs to the special issue Theranostic Frontiers in Neuro-Oncology
    View:76
    Download:6
    Times Cited: 0
    Open Access
    Review
    Clinical applications of liquid biopsy in HPV-negative and HPV-positive head and neck squamous cell carcinoma: advances and challenges
    Head and neck squamous cell carcinomas (HNSCCs) represent the most common epithelial tumors that arise from mucosa of the oral cavity, pharynx, and larynx. The development of HNSCCs is usually assoc [...] Read more.
    Mariana Chantre-Justino ... Lucas Delmonico
    Published: August 31, 2022 Explor Target Antitumor Ther. 2022;3:533–552
    DOI: https://doi.org/10.37349/etat.2022.00099
    This article belongs to the special issue The Implementation of Liquid Biopsy in Clinical Practice for Different Solid Tumor
    View:388
    Download:33
    Times Cited: 0
    Open Access
    Review
    miRNA therapeutics in precision oncology: a natural premium to nurture
    The dynamic spectrum of microRNA (miRNA) has grown significantly over the years with its identification and exploration in cancer therapeutics and is currently identified as an important resource fo [...] Read more.
    Chakresh Kumar Jain ... R Suresh Kumar
    Published: August 31, 2022 Explor Target Antitumor Ther. 2022;3:511–532
    DOI: https://doi.org/10.37349/etat.2022.00098
    View:238
    Download:29
    Times Cited: 0
    Open Access
    Review
    Myeloid-derived suppressor cells in colorectal cancer: prognostic biomarkers and therapeutic targets
    Myeloid-derived suppressor cells (MDSCs) are a group of immature myeloid cells, which are expanded in most cancer patients. MDSCs suppress host immune responses, leading to cancer growth and progres [...] Read more.
    Mohammad A. Al-Mterin, Eyad Elkord
    Published: August 31, 2022 Explor Target Antitumor Ther. 2022;3:497–510
    DOI: https://doi.org/10.37349/etat.2022.00097
    This article belongs to the special issue Cancer Immunotherapy and Tumor Microenvironment
    View:321
    Download:18
    Times Cited: 0
    Open Access
    Review
    Endocrine therapy resistance: what we know and future directions
    Endocrine resistance is a major hurdle in the treatment of estrogen receptor (ER)-positive breast cancer. When abnormally regulated, molecular signals responsible for cellular proliferation, as well [...] Read more.
    David Musheyev, Anya Alayev
    Published: August 31, 2022 Explor Target Antitumor Ther. 2022;3:480–496
    DOI: https://doi.org/10.37349/etat.2022.00096
    This article belongs to the special issue Endocrine Resistant Breast Cancer
    View:308
    Download:8
    Times Cited: 0
    Open Access
    Review
    A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors
    Multiple myeloma (MM) is a blood cancer that derives from plasma cells (PCs), which will accumulate in the bone marrow (BM). Over time, several drugs have been developed to treat this disease that i [...] Read more.
    Vincenzo Raimondi ... Nicola Giuliani
    Published: August 31, 2022 Explor Target Antitumor Ther. 2022;3:463–479
    DOI: https://doi.org/10.37349/etat.2022.00095
    This article belongs to the special issue Off-label drugs and -omics data in cancer treatment
    View:314
    Download:17
    Times Cited: 0
    Open Access
    Review
    Current strategies for the design of PROTAC linkers: a critical review
    PROteolysis TArgeting Chimeras (PROTACs) are heterobifunctional molecules consisting of two ligands; an “anchor” to bind to an E3 ubiquitin ligase and a “warhead”  [...] Read more.
    Robert I. Troup ... Matthias G. J. Baud
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:273–312
    DOI: https://doi.org/10.37349/etat.2020.00018
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:14089
    Download:1975
    Open Access
    Review
    The impact of tumour pH on cancer progression: strategies for clinical intervention
    Dysregulation of cellular pH is frequent in solid tumours and provides potential opportunities for therapeutic intervention. The acidic microenvironment within a tumour can promote migration, invasi [...] Read more.
    Carol Ward ... Simon P Langdon
    Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:71–100
    DOI: https://doi.org/10.37349/etat.2020.00005
    View:9743
    Download:513
    Open Access
    Review
    Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors
    Chronic lymphocytic leukemia is a common form of leukemia and is dependent on growth-promoting signaling via the B-cell receptor. The Bruton tyrosine kinase (BTK) is an important mediator of B-cell  [...] Read more.
    Rachael Arthur ... Graham Packham
    Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:131–152
    DOI: https://doi.org/10.37349/etat.2020.00009
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:5426
    Download:232
    Open Access
    Review
    Inhibitors of the Fanconi anaemia pathway as potential antitumour agents for ovarian cancer
    The Fanconi anaemia (FA) pathway is an important mechanism for cellular DNA damage repair, which functions to remove toxic DNA interstrand crosslinks. This is particularly relevant in the context of [...] Read more.
    Sarah J Taylor ... Simon P Langdon
    Published: February 29, 2020 Explor Target Antitumor Ther. 2020;1:26–52
    DOI: https://doi.org/10.37349/etat.2020.00003
    View:4246
    Download:142
    Times Cited: 0
    Open Access
    Review
    Targeted inhibition of mRNA translation initiation factors as a novel therapeutic strategy for mature B-cell neoplasms
    Cancer development is frequently associated with dysregulation of mRNA translation to enhance both increased global protein synthesis and translation of specific mRNAs encoding oncoproteins. Thus, t [...] Read more.
    Joe Taylor ... Graham Packham
    Published: February 29, 2020 Explor Target Antitumor Ther. 2020;1:3–25
    DOI: https://doi.org/10.37349/etat.2020.00002
    View:3861
    Download:107
    Open Access
    Review
    Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma
    Colorectal carcinoma (CRC) is an heterogeneous disease in which different genetic alterations play a role in its pathogenesis and progression and offer potential for therapeutic intervention. The re [...] Read more.
    Anna Maria Rachiglio ... Nicola Normanno
    Published: February 29, 2020 Explor Target Antitumor Ther. 2020;1:53–70
    DOI: https://doi.org/10.37349/etat.2020.00004
    View:3574
    Download:124
    Open Access
    Review
    Current strategies for the design of PROTAC linkers: a critical review
    PROteolysis TArgeting Chimeras (PROTACs) are heterobifunctional molecules consisting of two ligands; an “anchor” to bind to an E3 ubiquitin ligase and a “warhead”  [...] Read more.
    Robert I. Troup ... Matthias G. J. Baud
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:273–312
    DOI: https://doi.org/10.37349/etat.2020.00018
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:14089
    Download:1975
    Open Access
    Review
    The impact of tumour pH on cancer progression: strategies for clinical intervention
    Dysregulation of cellular pH is frequent in solid tumours and provides potential opportunities for therapeutic intervention. The acidic microenvironment within a tumour can promote migration, invasi [...] Read more.
    Carol Ward ... Simon P Langdon
    Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:71–100
    DOI: https://doi.org/10.37349/etat.2020.00005
    View:9743
    Download:513
    Open Access
    Review
    Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors
    Chronic lymphocytic leukemia is a common form of leukemia and is dependent on growth-promoting signaling via the B-cell receptor. The Bruton tyrosine kinase (BTK) is an important mediator of B-cell  [...] Read more.
    Rachael Arthur ... Graham Packham
    Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:131–152
    DOI: https://doi.org/10.37349/etat.2020.00009
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:5426
    Download:232
    Open Access
    Review
    PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors
    BCL-XL is an anti-apoptotic protein that plays an important role in tumorigenesis, metastasis, and intrinsic or therapy-induced cancer drug resistance. More recently, BCL-XL has also been identified [...] Read more.
    Peiyi Zhang ... Guangrong Zheng
    Published: August 31, 2020 Explor Target Antitumor Ther. 2020;1:259–272
    DOI: https://doi.org/10.37349/etat.2020.00017
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:3373
    Download:196
    Open Access
    Review
    Novel approaches for the rational design of PROTAC linkers
    Proteolysis targeting chimeras (PROTACs) represent a promising class of hetero-bivalent molecules that facilitate ubiquitination of a target protein by simultaneously binding and bringing together b [...] Read more.
    Almaz Zagidullin ... Emil Bulatov
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:381–390
    DOI: https://doi.org/10.37349/etat.2020.00023
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:2637
    Download:191
    Open Access
    Review
    Targeting HER2 in breast cancer: new drugs and paradigms on the horizon
    About 15–20% of all breast cancers (BCs) are defined human epidermal growth factor receptor 2 (HER2)-positive, based on the overexpression of HER2 protein and/or amplification [...] Read more.
    Paolo Tarantino ... Giuseppe Curigliano
    Published: April 30, 2021 Explor Target Antitumor Ther. 2021;2:139–155
    DOI: https://doi.org/10.37349/etat.2021.00037
    View:2829
    Download:160
    Open Access
    Review
    Current strategies for the design of PROTAC linkers: a critical review
    PROteolysis TArgeting Chimeras (PROTACs) are heterobifunctional molecules consisting of two ligands; an “anchor” to bind to an E3 ubiquitin ligase and a “warhead”  [...] Read more.
    Robert I. Troup ... Matthias G. J. Baud
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:273–312
    DOI: https://doi.org/10.37349/etat.2020.00018
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:14089
    Download:1975
    Open Access
    Review
    The impact of tumour pH on cancer progression: strategies for clinical intervention
    Dysregulation of cellular pH is frequent in solid tumours and provides potential opportunities for therapeutic intervention. The acidic microenvironment within a tumour can promote migration, invasi [...] Read more.
    Carol Ward ... Simon P Langdon
    Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:71–100
    DOI: https://doi.org/10.37349/etat.2020.00005
    View:9743
    Download:513
    Open Access
    Review
    Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors
    Chronic lymphocytic leukemia is a common form of leukemia and is dependent on growth-promoting signaling via the B-cell receptor. The Bruton tyrosine kinase (BTK) is an important mediator of B-cell  [...] Read more.
    Rachael Arthur ... Graham Packham
    Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:131–152
    DOI: https://doi.org/10.37349/etat.2020.00009
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:5426
    Download:232
    Open Access
    Review
    Potential of guggulsterone, a farnesoid X receptor antagonist, in the prevention and treatment of cancer
    Cancer is one of the most dreadful diseases in the world with a mortality of 9.6 million annually. Despite the advances in diagnosis and treatment during the last couple of decades, it still remains [...] Read more.
    Sosmitha Girisa ... Ajaikumar B. Kunnumakkara
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:313–342
    DOI: https://doi.org/10.37349/etat.2020.00019
    This article belongs to the special issue Targeting Transcription Factors for Cancer Therapy
    View:1956
    Download:51
    Open Access
    Review
    Targeted inhibition of mRNA translation initiation factors as a novel therapeutic strategy for mature B-cell neoplasms
    Cancer development is frequently associated with dysregulation of mRNA translation to enhance both increased global protein synthesis and translation of specific mRNAs encoding oncoproteins. Thus, t [...] Read more.
    Joe Taylor ... Graham Packham
    Published: February 29, 2020 Explor Target Antitumor Ther. 2020;1:3–25
    DOI: https://doi.org/10.37349/etat.2020.00002
    View:3861
    Download:107
    Open Access
    Review
    Role of liquid biopsy for thoracic cancers immunotherapy
    Immunotherapy has shifted the therapeutic landscape in thoracic cancers. However, assessment of biomarkers for patient selection and disease monitoring remain challenging, especially considering the [...] Read more.
    Raimondo Di Liello ... Paloma Martín-Martorell
    Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:183–199
    DOI: https://doi.org/10.37349/etat.2020.00012
    This article belongs to the special issue Liquid Biopsy in Thoracic Cancer
    View:2301
    Download:48
    Special Issues